GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites
Nutrients · 05.02.2026 · 18 (3) · 531
DOI: 10.3390/nu18030531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 05.02.2026. Verfasst von Bing Gong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China. Hauptthemen laut MEDLINE: Liraglutide, Sepsis, Gastrointestinal Microbiome, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guobing Chen, Yunnan Province Medical High-level Talents Program, Kunming University of Science and Technology Joint Special Project.
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis-induced organ dysfunction poses a significant clinical challenge with limited therapeutic options. This study investigated the therapeutic potential of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide in sepsis and its underlying mechanisms, focusing on modulation of the gut microbiota-derived metabolome.
Methods
Public transcriptomic data analysis identified overlapping targets between liraglutide and sepsis-related genes. In a murine cecal ligation and puncture (CLP) model, liraglutide treatment was evaluated for its effects on survival, systemic inflammation, and organ injury. The gut microbiota composition and fecal metabolome were assessed via 16S rRNA sequencing and UPLC-MS. We also measured plasma GLP-1 in sepsis patients and examined the microbiota-dependency of liraglutide’s effects using antibiotic-depleted mice and fecal microbiota transplantation (FMT) from liraglutide-treated mice. Additionally, citrulline, a key identified metabolite, was functionally validated both in vitro and in a clinical cohort.
Results
Liraglutide significantly improved survival, reduced pro-inflammatory cytokines, and alleviated lung, liver, and colon damage in septic mice. It partially restored sepsis-induced gut dysbiosis and modulating associated metabolites, including increasing citrulline. The survival benefit of liraglutide was abolished in microbiota-depleted mice, while FMT from liraglutide-treated mice conferred protection against sepsis, confirming the gut microbiota as a critical mediator. Furthermore, citrulline exhibited direct anti-inflammatory properties in cellular assays, and its plasma levels were negatively correlated with sepsis biomarkers (PCT and CRP) in patients.
Conclusions
Taken together, our findings indicate that liraglutide mitigates sepsis by modulating the gut microbiota and regulating associated metabolic pathways. Citrulline may represent a potential microbial mediator or exploratory biomarker within this axis, warranting further mechanistic investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
ORCID-Profile: Bing Gong, Guobing Chen, Heng Su
Förderung
- Guobing Chen
- Yunnan Province Medical High-level Talents Program
- Kunming University of Science and Technology Joint Special Project
- Yunnan Basic Research Program
- “Famous Doctors” Special Project of “Ten Thousand Experts” Program, Yunnan Province
Zitieren
APA
Gong, B., Shi, Z., Qi, J., Wang, F., Chen, G., & Su, H. (2026). GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites. Nutrients, 18(3), 531. https://doi.org/10.3390/nu18030531
Vancouver
Gong B, Shi Z, Qi J, Wang F, Chen G, Su H. GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites. Nutrients. 2026;18(3):531. doi:10.3390/nu18030531
BibTeX
@article{Gong2026,
author = {Gong, Bing and Shi, Zhuang'e and Qi, Jialong and Wang, Fuping and Chen, Guobing and Su, Heng},
title = {GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {3},
pages = {531},
doi = {10.3390/nu18030531}
}
EUVIMED